418,505 Shares in Exagen Inc. (NASDAQ:XGN) Purchased by Driehaus Capital Management LLC

Driehaus Capital Management LLC acquired a new stake in Exagen Inc. (NASDAQ:XGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 418,505 shares of the company's stock, valued at approximately $1,716,000. Driehaus Capital Management LLC owned approximately 2.37% of Exagen as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Corient Private Wealth LLC acquired a new stake in shares of Exagen during the 4th quarter valued at approximately $45,000. Virtu Financial LLC bought a new position in Exagen during the 4th quarter worth $46,000. Marshall Wace LLP bought a new position in Exagen during the 4th quarter worth $66,000. Northern Trust Corp grew its stake in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after buying an additional 2,630 shares during the last quarter. Finally, Palumbo Wealth Management LLC grew its stake in Exagen by 13.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock worth $355,000 after buying an additional 10,340 shares during the last quarter. Institutional investors and hedge funds own 75.25% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on XGN. BTIG Research restated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Cantor Fitzgerald lowered their price objective on Exagen from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Thursday. Canaccord Genuity Group upped their price objective on Exagen from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, William Blair reissued an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th.

Exagen Price Performance

XGN stock traded up $0.07 during trading hours on Thursday, hitting $5.89. 105,069 shares of the stock traded hands, compared to its average volume of 108,745. The stock has a 50-day simple moving average of $4.70 and a 200 day simple moving average of $4.17. Exagen Inc. has a one year low of $1.67 and a one year high of $7.20. The company has a market cap of $105.94 million, a P/E ratio of -6.26 and a beta of 1.50. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. During the same period in the prior year, the business posted ($0.19) earnings per share. Equities analysts forecast that Exagen Inc. will post -0.88 earnings per share for the current year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).